---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-118322"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:27:57.978773+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty Q1 net income $2.4M, total revenues $15.9M; adds Castle Creek royalty, sells Kinnate assets

## Summary
- Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).
- Cash receipts $18.0M in Q1, including $13.4M royalties and $4.6M milestones; cash $95.0M at March 31.
- Acquired Phase 3 royalty interest in Castle Creek's D-Fi (DEB) for $5M; sold all unpartnered Kinnate assets.
- Milestone: $4.0M from Day One/Ipsen MAA filing for tovorafenib with EMA; $3.0M net from Takeda Phase 3 start (Q2).
- Share repurchases: $0.5M for 25,828 shares; paid $1.4M in preferred dividends.

## SEC filing metadata
- accession: 0001193125-25-118322
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312525118322/0001193125-25-118322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312525118322/d905797d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-118322
- JSON: https://secwatch.observer/filing/0001193125-25-118322.json
- Plain text: https://secwatch.observer/filing/0001193125-25-118322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.